Compare Ecolab Inc. (ECL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs IDEXX Laboratories, Inc. — how do they compare? Ecolab Inc. trades at $281.2 (market cap $79.79B), while IDEXX Laboratories, Inc. trades at $570.89 (market cap $46.22B). The key difference: Ecolab Inc. is the larger of the two by market cap, and Ecolab Inc. pays a 1.03% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ECL | IDXX | |
|---|---|---|
Market Cap | $79.79B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $766.68 |
52-Week Low | $245.73 | $526.44 |
Enterprise Value | $88.57B | $47.12B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $284.4, down slightly (-0.27%) on the day, with a bullish technical signal and strong analyst support (78% buy ratings). The company reported solid Q2 2026 earnings of $2.09 per share, beating estimates, and raised full-year guidance. Revenue growth is steady, with 2025 revenue at $16.08B, and profitability remains robust with a net income margin of 12.57%. Recent news highlights institutional activity and the completion of the $4.75B CoolIT acquisition, strengthening its high-tech portfolio.
The outlook is positive, driven by earnings momentum, strategic acquisitions, and a consensus price target of $327.90 implying ~15% upside. Key risks include execution of integration for recent acquisitions, input cost pressures, and broader market volatility. The stock presents a compelling opportunity for growth investors seeking exposure to a stable, dividend-paying company with digital and high-tech expansion drivers.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
